Jain Dharmendra, Choudhuri Jui, Chauhan Rajni, Dorwal Pranav, Sharma Deepak, Tiwari Aseem K, Raina Vimarsh
Molecular Genetics Laboratory, Department of Pathology and Laboratory Medicine, Medanta-The Medicity, Gurgaon, Haryana, India.
Chimera Transplant Research Foundation, Masjid Moth, New Delhi, India.
J Clin Lab Anal. 2018 Feb;32(2). doi: 10.1002/jcla.22237. Epub 2017 Apr 26.
Bead based flow cytometry and Luminex play a major role in identification of alloantibodies in renal transplant work-up. Strong sensitization events may lead to prozone phenomenon that can affect single antigen bead (SAB) assay and result in false negativity. However, this can also be due to high titer of other blocking antibodies. While methods like, heat inactivation, C1 inhibitor, Ethylene diamine tetra-acetic-acid and Dithio threitol treatment can remove interfering antibodies of complement and IgM, these methods are not optimal if false negativity is due to prozone effect, which is high titer of antibodies alone.
We hereby present a case of a highly sensitized renal transplant recipient with 64% panel reactive antibody positivity (PRA) and a subsequent negative SAB assay. This paradoxical finding hinted at SAB being a false negative result and serial dilutions were used to perform further tests.
Serum dilutions lead to positive flow based panel reactive antibody (PRA) and flow cytometry crossmatch (FCXM), with an increasing trend in FCXM.
In highly sensitized patients serial dilution should be considered during a transplant work-up to avoid missing any underlying antibodies. Serum dilution can be used as first option to circumvent prozone. Also, interference of other antibodies should not be labeled as prozone effect.
基于微珠的流式细胞术和Luminex技术在肾移植术前评估中鉴定同种抗体方面发挥着重要作用。强烈的致敏事件可能导致前带现象,这会影响单抗原微珠(SAB)检测并导致假阴性结果。然而,这也可能是由于其他封闭抗体的高滴度所致。虽然诸如热灭活、C1抑制剂、乙二胺四乙酸和二硫苏糖醇处理等方法可以去除补体和IgM的干扰抗体,但如果假阴性是由于仅抗体高滴度导致的前带效应,这些方法并不理想。
我们在此报告一例高度致敏的肾移植受者病例,其群体反应性抗体(PRA)阳性率为64%,随后SAB检测为阴性。这一矛盾的发现提示SAB为假阴性结果,因此采用系列稀释进行进一步检测。
血清稀释导致基于流式的群体反应性抗体(PRA)和流式细胞术交叉配型(FCXM)呈阳性,且FCXM呈上升趋势。
在高度致敏患者的移植术前评估中,应考虑采用系列稀释以避免遗漏任何潜在抗体。血清稀释可作为规避前带的首选方法。此外,不应将其他抗体的干扰标记为前带效应。